Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
Open accessThe DOI matches its Crossref record; 32 of the 35 references it cites were found in a registry or an index.
Abstract
PURPOSE: An important factor in the choice of therapy is the impact it has on the patient's quality of life. This survey aimed to understand treatment burden, treatment-related anxiety and worry, and practical issues such as appointment attendance and work absence in patients receiving injection therapy for diabetic macular edema (DME) or retinal vein occlusion (RVO). PATIENTS AND METHODS: A European sample of 131 retinal patients completed a detailed questionnaire to elucidate the impact of injection therapy on individuals with DME or RVO. RESULTS: RVO and DME greatly impact a patient's quality of life. An intensive injection regimen and the requirements for multiple hospital visits place a large practical burden on the patient. Each intravitreal injection appointment (including travel time) was reported to take an average of 4.5 hours, with a total appointment burden over 6 months of 13.5 hours and 20 hours for RVO and DME patients, respectively. This creates a significant burden on patient time and may make appointment attendance difficult. Indeed, 53% of working patients needed to take at least 1 day off work per appointment and 71% of patients required a carer's assistance at the time of the injection appointment, ~6.3 hours per injection. In addition to practical issues, three-quarters of patients reported experiencing anxiety about their most recent injection treatment, with 54% of patients reporting that they were anxious for at least 2 days prior to the injection. Patients' most desired improvement to their treatment regimen was to have fewer injections and to require fewer appointments, to achieve the same visual results. CONCLUSION: Patients' quality of life is clearly very affected by having to manage an intensive intravitreal injection regimen, with a considerable treatment burden having a large negative effect. Reducing the appointment burden to achieve the same visual outcomes and the provision of additional support for patients to attend appointments would greatly benefit those receiving intravitreal injection therapies for DME and RVO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the effectiveness of anti-VEGF injections in stabilizing and, even in some cases, reversing these conditions demonstrated in clinical trials [10], their high price compounded with their long-term associated care represent a strain on health systems and patients [11–13].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The repeated injections may take a significant toll on the patients’ emotional wellbeing and quality of life [11, 69], adversely affecting adherence and potentially leading to undertreatment and deterioration of the condition [70].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985 · cited 1×
“5% of patients with diabetes worldwide.(1) Globally, 26.”
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.024 · Cited by 1,122
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
The Impact of Comorbid Chronic Conditions on Diabetes Care
Piette, J. D., & Kerr, E. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-2078 · Cited by 731 · cited 2×
“an already demanding workload and who can only spend a limited amount of time with each patient.(22,40)”
The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study.
Klein, R., Klein, R., Moss, S. E., & Meuer, S. M. (2000) · PubMed · Cited by 636
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema
Ding, J., & Wong, T. Y. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0283-6 · Cited by 439 · cited 1×
“In the future, DME is set to increase as a public health problem due to aging populations in Europe, Africa, and the Middle East and the increased prevalence of diabetes, longer duration of diabetes, and older age at onset.(3,4) RVO is also an important and growing cause of vision loss, and after diabetic retinopathy,…”
Research works printed but not linked: 1
- [13]Weinberg DV Seddon JM Venous occlusive diseases of the retina Albert DM Jakobiec FA Principles and Practice of Ophthalmology 2 Philadelphia W.B. Saunders Company 1994 735 746
Cited by
Weiss, M., Sim, D. A., Herold, T., Schumann, R. G., Liegl, R., Kern, C., Kreutzer, T., Schiefelbein, J., Rottmann, M., Priglinger, S., et al. (2018) · Retina · doi:10.1097/iae.0000000000001892 · Cited by 155
“Sex (%) 45 men (41), 64 women (59) 87 men (64), 49 women (36) ,0.”
Coarse-to-fine classification for diabetic retinopathy grading using convolutional neural network
Wu, Z., Shi, G., Chen, Y., Shi, F., Chen, X., Coatrieux, G., Yang, J., Luo, L., & Li, S. (2020) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2020.101936 · Cited by 140
“Experimental results show that proposed CF-DRNet outperforms the comparative methods [6, 19] in the IDRiD database and Kaggle database.”
DMENet: Diabetic Macular Edema diagnosis using Hierarchical Ensemble of CNNs
Singh, R. K., & Gorantla, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0220677 · Cited by 97
Augustin, A. J., Bopp, S., Fechner, M., Holz, F. G., Sandner, D., Winkgen, A., Khoramnia, R., Neuhann, T. F., Warscher, M., Spitzer, M. S., et al. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119834474 · Cited by 74
Eter, N., Singh, R. P., Abreu, F. M., Asik, K., Basu, K., Baumal, C. R., Chang, A., Csaky, K. G., Hašková, Z., Lin, H., et al. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100111 · Cited by 86
“The burden of intravitreal anti-VEGF monotherapy and need for frequent clinic visits for treatment, monitoring, or both is high for patients with DME, their caregivers, and health care providers.(27,28) Despite the efficacy shown with intravitreal anti-VEGF monotherapy in clinical trials with monthly visits, many pati…”
Wykoff, C. C., Chakravarthy, U., Campochiaro, P. A., Bailey, C., Green, K., & Cunha-Vaz, J. G. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.11.034 · Cited by 75
Reitan, G., Haugen, I. B. K., Andersen, K., Bragadóttir, R., & Bindesbøll, C. (2023) · Clinical ophthalmology · doi:10.2147/opth.s409103 · Cited by 72
“A study that included patients from Germany, UK and Italy revealed that 53% needed to take at least one day off work and that they spent on average four and a half hours on the treatment day.(20) The majority of the patients in this survey report that they spend more than four hours on the treatment day.”
InfluentialNext-generation anti-VEGF agents for diabetic macular oedema
Iglicki, M., González, D. P., Loewenstein, A., & Zur, D. (2021) · Eye · doi:10.1038/s41433-021-01722-8 · Cited by 69
Iglicki, M., Lavaque, A. J., Ozimek, M. A., Negri, H. P., Okada, M., Chhablani, J. K., Busch, C., Loewenstein, A., & Zur, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200365 · Cited by 69
Rosenblatt, A., Udaondo, P., Cunha-Vaz, J., Sivaprasad, S., Bandello, F. M., Lanzetta, P., Kodjikian, L., Goldstein, M., Habot‐Wilner, Z., Loewenstein, A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.10.005 · Cited by 67
Self-citationGhanchi, F. D., Bourne, R., Downes, S. M., Gale, R. P., Rennie, C. A., Tapply, I. H., & Sivaprasad, S. (2022) · Eye · doi:10.1038/s41433-021-01766-w · Cited by 66
“However, all of these therapies are associated with a relatively high treatment burden [1]: for example, intravitreally administered anti-VEGF therapy can involve hospital visits for assessment and anti-VEGF injections every 1–2 months.”
Self-citationOptical coherence tomography in the management of diabetic macular oedema
Szeto, S., Lai, T. Y. Y., Vujosevic, S., Sun, J. K., Sadda, S. R., Tan, G. S. W., Sivaprasad, S., Wong, T. Y., & Cheung, C. Y.-L. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101220 · Cited by 70
Self-citationPessoa, B., Coelho, J., Correia, N. A., Ferreira, N., Beirão, J. M., & Meireles, A. (2017) · Ophthalmic Research · doi:10.1159/000484091 · Cited by 50
Fusi-Rubiano, W., Mukherjee, C., Lane, M., Tsaloumas, M. D., Glover, N., Kidess, A., Denniston, A. K., Palmer, H., Manna, A., & Morjaria, R. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0726-1 · Cited by 47
“Most patients want fewer injections and appointments, to achieve the same visual results [17].”
Meireles, A., Goldsmith, C., El-Ghrably, I. A., Erginay, A., Habib, M., Pessoa, B., Coelho, J., Patel, T. P., Tadayoni, R., Massin, P., et al. (2017) · Eye · doi:10.1038/eye.2016.303 · Cited by 39
Fusi-Rubiano, W., Blow, R. R., Lane, M., Morjaria, R., & Denniston, A. K. (2018) · Ophthalmology and Therapy · doi:10.1007/s40123-018-0145-7 · Cited by 35
Kodjikian, L., Baillif, S., Creuzot-Garcher, C. P., Delyfer, M., Matonti, F., Weber, M., & Mathis, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010072 · Cited by 35
“Considering that 42% of a European sample of 131 retinal patients would prefer having fewer injections for the same results, one can see FAc implants as a way to decrease treatment burden and improve patient’s quality of life [55].”
Pető, T., Akerele, T., Sagkriotis, A., Zappacosta, S., Clemens, A., & Chakravarthy, U. (2021) · Diabetic Medicine · doi:10.1111/dme.14746 · Cited by 35
BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion
Kuhli-Hattenbach, C., Abreu, F. M., Arrisi, P., Basu, K., Danzig, C. J., Guymer, R. H., Hašková, Z., Heier, J. S., Kotecha, A., Liu, Y., et al. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100302 · Cited by 41
“21 e 23 Of note, patients with CRVO who achieve vision gains in clinical trials have also been shown to, on average, experience best-corrected visual acuity (BCVA) loss with subsequent pro re nata dosing, with less than monthly monitoring, in long-term extension studies.”
Mansour, S. E., Kiernan, D. F., Roth, D. B., Eichenbaum, D. A., Holekamp, N. M., Kaba, S. E., & Werts, E. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-315984 · Cited by 33
“23 Other DMO therapies have been shown to provide improvement in vision and macular oedema 24 25 ; however, the injection protocol for anti-VEGF agents, for example, is up to five consecutive monthly administrations during the induction phase followed by monthly or bimonthly injections.”
Khanani, A. M., Campochiaro, P. A., Graff, J. M., Marcus, D. M., Miller, D. M., Mittra, R. A., Regillo, C. D., Sheth, V. S., Bobbala, A., Gune, S., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0006 · Cited by 39
Kodjikian, L., Bandello, F. M., de Smet, M. D., Dot, C., Zarranz‐Ventura, J., Loewenstein, A., Sudhalkar, A. A., Bilgic, A., Cunha-Vaz, J. G., Dirven, W., et al. (2022) · European Journal of Ophthalmology · doi:10.1177/11206721221080288 · Cited by 33
“In fact, half of DME patients present anxiety two days prior to the injection and 42% consider that fewer injections associated with functional and anatomic response are an improvement to the treatment regimen.(9) Moreover, impairment of ocular surface after injections has been shown to alter quality of life immediate…”
Kiss, S., Grishanin, R., Nguyen, A., Rosario, R., Greengard, J. S., Nieves, J., Gelfman, C. M., & Gasmi, M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.007 · Cited by 29
“Molecular Therapy: Me This is an open access article under the CC BY-NCposes a significant burden on patients, caregivers, and the healthcare system, and can result in decreased compliance followed by disease progression.(14,15) Minimizing this treatment burden while maintaining treatment efficacy remains an unmet nee…”
Sam-Oyerinde, O. A., & Patel, P. J. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00672-6 · Cited by 33
Giovannini, A., Parravano, M., Ricci, F., & Bandello, F. M. (2018) · European Journal of Ophthalmology · doi:10.1177/1120672118781236 · Cited by 29
Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations
Wong, D. T., Aboobaker, S., Maberley, D., Sharma, S., & Yoganathan, P. (2025) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2024-001967 · Cited by 30
El-Ghrably, I. A., STEEL, D. H., Habib, M., Vaideanu-Collins, D., Manvikar, S., & Hillier, R. J. (2017) · European Journal of Ophthalmology · doi:10.5301/ejo.5000929 · Cited by 25
“A high frequency of intravitreal injections has been shown to affect quality of life and to increase anxiety and work absences in patients with DME (23); patients’ most desired improvement to their treatment regimen was to have fewer injections and to require fewer appointments, to achieve the same visual results (23).”
Mushtaq, Y., Mushtaq, M., Gatzioufas, Z., Ripa, M., Motta, L., & Panos, G. D. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s403259 · Cited by 25
“An increase in the frequency of injections has also been shown to decrease patients’ quality of life, causing an increase in work leave and anxiety.(70)”
Vinge, E., & Bro, T. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15783 · Cited by 24
“However, a study including Germany, Italy and the UK has shown an average time of 4.5 h per intra-vitreal treatment for diabetic macular oedema or retinal vein occlusion (Sivaprasad & Oyetunde, 2016).”
InfluentialDowney, L., Acharya, N., Devonport, H., Gale, R. P., Habib, M., Manjunath, V., Mukherjee, R., & Severn, P. S. (2021) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000696 · Cited by 23
“38 The additional pressures on the system brought by the pandemic—including a reduction in capacity due to social distancing and staff sickness, and a desire among patients with diabetes (who are at greater risk of COVID-19 complications) to attend hospital less frequently—mean that it is more…”
Martel, A., Nahon‐Estève, S., Martini, K., Almairac, F., & Baillif, S. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04699-4 · Cited by 25
Araújo, T., Aresta, G., Schmidt-Erfurth, U. M., & Bogunović, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-43018-9 · Cited by 30
Habib, M. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0006 · Cited by 16
Friedman, S. M., Xu, Y., Sherman, S. A., Kuznik, A., Mojebi, A., Keeping, S. T., Chan, K., Leng, T., & Patel, N. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01247-3 · Cited by 20
“…DME diabetic macular edema, nAMD neovascular age-related macular degeneration, NMA network meta-analysis, T&E treat and extend. a Comparison was statistically significant (95% Crls did not cross 0) who were treated with fixed or flexible regimens of other anti-VEGF agents, including faricimab [51].”
Falcão, M. S. (2019) · Ophthalmologica · doi:10.1159/000505070 · Cited by 15
Adán, A., López, F. A. C., Figueroa, M. S., Cervera, E., Ascaso, F. J., Udaondo, P., Abraldes, M. J., Reyes, M., Pazos, M., Pessoa, B., et al. (2020) · Clinical ophthalmology · doi:10.2147/opth.s252359 · Cited by 15
Mehta, H., Fraser‐Bell, S., Nguyen, V., Lim, L. L., & Gillies, M. C. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.06.010 · Cited by 15
Rose, M. A., Vukicevic, M., Koklanis, K., Rees, G., Sandhu, S. S., & Itsiopoulos, C. (2018) · Psychology Health & Medicine · doi:10.1080/13548506.2018.1533249 · Cited by 15
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025) · Eye · doi:10.1038/s41433-024-03529-9 · Cited by 14
“Most of these injection schedules have a significant burden to the patients in terms of anxiety and quality of life [12].”
Self-citationDinah, C. B., Dodds, M., Lotery, A. J., Salvatore, S., Fletcher, E. C., Lake, A. V. R., Parker, A., Pereira, L., Retiere, A.-C., Saffar, I., et al. (2025) · Eye · doi:10.1038/s41433-025-04089-2 · Cited by 20
TEMPORARY REMOVAL: Four-Year Outcomes of Faricimab in Diabetic Macular Edema
Sheth, V. S., Schlottmann, P. G., Lai, T. Y. Y., Abreu, F. M., Chang, A., Eter, N., Gibson, K., Hu, A. Y. H., Korobelnik, J., Kotak, A., et al. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.01.001 · Cited by 18
RetractedHerold, T., Langer, J., Vounotrypidis, E., Kernt, M., Liegl, R., & Priglinger, S. G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202483 · Cited by 14
Quhill, F. M., & Beiderbeck, A. B. (2017) · Global & Regional Health Technology Assessment · doi:10.5301/grhta.5000268 · Cited by 14
“Fewer intravitreal injections also translates into greater convenience (for patients, carers and healthcare professionals (9)), fewer physician visits and less pressure on clinics.”
Mourtzoukos, S. (2017) · Expert Review of Ophthalmology · doi:10.1080/17469899.2017.1285698 · Cited by 14
“Patient compliance Sivaprasad and Oyetunde [10] surveyed 131 retinal patients in Europe to assess the impact of injection therapy on individuals with DMO or retinal vein occlusion.”
Sivaprasad, S., Cheung, C. M. G., Gliem, M., Wykoff, C. C., Zippel, N., Ishida, S., & Nguyen, Q. D. (2025) · Eye · doi:10.1038/s41433-025-03835-w · Cited by 17
“Injection appointments, including travel time, have been estimated to take an average of 4.5 h, and the total injection appointment burden over 6 months has been estimated at 20 h per patient [85].”
InfluentialSelf-citationPető, T., Pearce, I., Talks, J. S., Salvo, G. D., Patel, P. J., Silva, S. R. D., Gale, R. P., Sivaprasad, S., Varma, D., Reynolds, R., et al. (2025) · Eye · doi:10.1038/s41433-025-04059-8 · Cited by 13
“…between clinical trials and real-world outcomes has largely been attributed to the treatment burden on patients, caregivers and clinics/healthcare systems associated with chronic, frequent intravitreal injections (which may be as often as every 4 weeks) and regular follow-up visits [5, 6].”
Self-citationIntravitreal DEX Implant for the Treatment of Diabetic Macular Edema: A Review of National Consensus
Spinetta, R., Petrillo, F., Reibaldi, M., Tortori, A., Mazzoni, M., Metrangolo, C., Gelormini, F., Ricardi, F., & Giordano, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102461 · Cited by 16
“Other emotional factors, encompassing feelings of frustration, treatment-related anxiety, and needle phobia, should all be taken into account [2,3].”
InfluentialSéjournet, L., Mathis, T., Vermot-Desroches, V., Serra, R., Fenniri, I., Denis, P., & Kodjikian, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091183 · Cited by 13
Giunta, M., Meunier, L.-P. G., Nixon, D. R., Steeves, J., & Noble, J. (2022) · Clinical ophthalmology · doi:10.2147/opth.s376199 · Cited by 14
“Patient anxiety related to their intravitreal injection was also found to be an important burden in a European study, with 93% of 131 patients reporting anxiety, including 54% for ≥2 days prior to their appointment.(17) Patient-reported effects of this anxiety included inability to relax (58%), disrupted sleep (26%),…”
Loewenstein, A., Berger, A. R., Daly, A., Creuzot-Garcher, C. P., Gale, R. P., Ricci, F., Zarranz‐Ventura, J., & Guymer, R. H. (2023) · Eye · doi:10.1038/s41433-023-02540-w · Cited by 15
Fernández‐Vigo, J. I., Burgos‐Blasco, B., Calvo-González, C., Escobar-Moreno, M. J., Shi, H., Jiménez-Santos, M., Valverde-Megías, A., Reche-Frutos, J., López-Guajardo, L., & Donate-López, J. (2021) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2020.11.008 · Cited by 12
Treat and extend regimen for diabetic macular oedema—a systematic review and meta-analysis
Lim, S. Y., Wong, W., Seah, I. Y. J., Chan, H. W., Su, X., Gopal, L., & Yuen, Y. S. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05770-y · Cited by 11
Abdalla, S., Westborg, I., Pulkki‐Brännström, A., & Norberg, H. (2024) · Acta Ophthalmologica · doi:10.1111/aos.16774 · Cited by 11
“Extending the intervals between treatments would also benefit patients as they often find it demanding to attend frequent appointments at the eye clinic (Boyle et al., 2018; Droege et al., 2013; Sivaprasad & Oyetunde, 2016).”
Tabano, D. C., Watane, A., Gale, R. P., Cox, O., Hill, S., Longworth, L., Oluboyede, Y., Ahmed, A. M., & Patel, N. A. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01180-5 · Cited by 15
“Similarly, physicians and other healthcare workers also see improved treatment durability as one of the greatest unmet needs in the treatment of retinal diseases [24].”
Ziemssen, F., Sylvanowicz, M., Amoaku, W. M. K., Aslam, T. M., Eldem, B., Finger, R. P., Gale, R. P., Kodjikian, L., Korobelnik, J., Lin, X., et al. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-01060-4 · Cited by 13
Coelho, J., Pessoa, B., & Meireles, A. (2019) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841418820755 · Cited by 10
Adherence of patients with diabetic macular oedema to intravitreal injections: A systematic review
Rose, M. A., Vukicevic, M., & Koklanis, K. (2020) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13845 · Cited by 9
Fernández-Vigo, J. I., Burgos-Blasco, B., Calvo-González, C., Escobar-Moreno, M. J., Shi, H., Jiménez-Santos, M., Valverde-Megías, A., Reche-Frutos, J., López-Guajardo, L., & Donate-López, J. (2021) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2020.11.010 · Cited by 8
Holden, S. E., Currie, C. J., & Owens, D. R. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1366663 · Cited by 8
Augustin, A. J., Feltgen, N., Haritoglou, C., Hoerauf, H., Maier, M. M., Mardin, C. Y., & Schargus, M. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1024-4089 · Cited by 8
“Die relativ häufige Applikation von zugelassenen VEGF-Hemmern ist mit hohen Kosten und einer großen Belastung für den Patienten verbunden [48].”
Adams, O. E., Schechet, S. A., & Hariprasad, S. M. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120901691 · Cited by 8
Patient experience of anti-vegf intravitreal injection
Gualino, V., Fourmaux, E., Grenet, T., Zerbib, J., & Wolff, B. (2020) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2020.02.006 · Cited by 7
Nguyen, Q. D., Ehlers, J. P., Boyer, D. S., Jin, X., Giani, A., Ehrlich, M. S., On behalf of the ROBIN study investigators, Brucker, A. J., Hu, A. Y. H., Fawzi, A. A., et al. (2024) · Eye · doi:10.1038/s41433-024-03017-0 · Cited by 6
“Furthermore, panretinal photocoagulation can be associated with loss of visual field, decreased night vision and increased macular oedema, and there is a burden associated with receiving intravitreal treatment that can lead to non-compliance and, in turn, lower efficacy [15, 16].”
Self-citationCarnevali, A., Bacherini, D., Metrangolo, C., Chiosi, F., Viggiano, P., Astarita, C., Gallinaro, V., & Bonfiglio, V. M. E. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1454591 · Cited by 7
The current role of steroids in diabetic macular edema
Cicinelli, M. V., Cavalleri, M., Lattanzio, R., & Bandello, F. M. (2020) · Expert Review of Ophthalmology · doi:10.1080/17469899.2020.1729743 · Cited by 6
Treatment Patterns and Long-term Outcomes with Anti–VEGF Therapy for Retinal Vein Occlusion
Ip, M. S., Modi, Y. S., Fekrat, S., Gibson, K., Boucher, N., Arrisi, P., Ishii, F., Liu, Y., Paris, L. P., Fenech, M. T., et al. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.05.025 · Cited by 5
Kuznik, A., Coughlan, A., Pinsent, A., Toro‐Díaz, H., Sherman, S. A., & Patel, N. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01236-6 · Cited by 8
“Although associated with improved visual outcomes [6, 12], the need for frequent intravitreal anti‑VEGF injections results in a substantial burden on patients [34, 45].”
Bhisitkul, R. B., Campochiaro, P. A., Blotner, S. D., Quezada-Ruiz, C., Liu, M., & Hašková, Z. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-323120 · Cited by 5
“17 Moreover, when asked to recommend improvements to their current treatment, patients desired fewer injections (42% of those surveyed) and fewer appointments (22%).”
Raman, V. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1523720 · Cited by 5
Ferroni, M., Gaetano, F. D., Cereda, M. G., & Boschetti, F. (2020) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2020.10.004 · Cited by 5
Wei, W., Chen, Y., Hu, B., Zhao, M., Han, M. L. K., Dai, H., Uy, H. S., Chen, M. Y., Wang, K., Jiao, J., et al. (2021) · Clinical ophthalmology · doi:10.2147/opth.s325618 · Cited by 5
Do new drugs for diabetic macular edema offer a safer option?
Mathis, T., & Kodjikian, L. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2160442 · Cited by 5
“DME patients may find it hard to attend all of these ophthalmology appointments, especially as they usually need regular follow-up with other specialists such as endocrinologists, nephrologists, etc [15,16].”
Spital, G., Schmitz-Valckenberg, S., Müller, B., Liczenczias, E., Chang, P., Heimes, B., Ziemssen, F., Liakopoulos, S., & For the ORCA study group (2024) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-024-06579-7 · Cited by 4
“CG, cannot grade; NA, not assessable; IRF, intraretinal fluid; RC, reading centre; SD-OCT, spectral domain-optical coherence tomography; SRF, subretinal fluid B C A real-world settings have been noted with regards to both injection frequency and VA outcomes [19–24].”
Hirano, T., Murata, T., Nakao, S., Shimura, M., Nozaki, M., Suzuma, K., Nagaoka, T., Sugimoto, M., Takamura, Y., Murakami, T., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311484 · Cited by 4
Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective
Poley, M. J., Armstrong, N., Yang, H., Patel, M., Stirk, L., Al, M., & Ramos, I. C. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01522-y · Cited by 4
“Frequent appointments and injections (on average, 7–15 anti–vascular endothelial growth factor [anti-VEGF] injections across 3 years of treatment [8, 9]) place a considerable burden on patients, caregivers, and the healthcare system [10–13].”
Byun, M., Osher, J. M., & Riemann, C. D. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2019-000416 · Cited by 4
Pacella, F., Pacella, E., Battagliola, E. T., Malvasi, M., Scalinci, S. Z., Turchetti, P., Salducci, M., Lucchino, L., & Arrico, L. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211020203 · Cited by 4
Risk of Infectious Endophthalmitis From a Resident-Performed Intravitreal Injection
Day, H. R., Law, J. C., & Lindsey, J. L. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420972562 · Cited by 4
Genome-Wide Association Study to Identify Genetic Variants Associated With Diabetic Maculopathy
Gurung, R. L., Nangia, C., Cai, T., FitzGerald, L. M., McComish, B. J., Liu, E., Kaidonis, G., Ridge, B., Hewitt, A. W., Vote, B. J. T., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.3.55 · Cited by 3
“56 SNPs on chromosome 13 have been found to be associated with monocyte count, which is reported to influence DME.”
Patient and Physician Perspectives on the Management of Diabetic Macular Edema
Warren, B., Donohoe, M., Sivaprasad, S., & Wykoff, C. C. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01268-y · Cited by 3
“Some studies also report that IVT injection-related anxiety persists in many patients even when they become more experienced with injection [3, 20].”
InfluentialSelf-citationChen, K. M., Chan, H.-C., & Chan, C.-M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179034 · Cited by 3
Tanwani, A., Safdar, N., Ali, A., Karimaghaei, C., Schmitz-Brown, M., Rehmani, A., & Gupta, P. K. (2021) · Life · doi:10.3390/life12010051 · Cited by 3
“Patients have to worry about practical inconveniences, such as cost of injections, absences from work, and reliance on family members and caregivers to accompany them to the frequent visits, as well as emotional stressors of frustration, treatment anxiety, and needle phobia [16].”
Wen, Q., Karcher, H., Wright, D. M., Sinha, S. B., Chakravarthy, U., Santos, C., Igwe, F., Salongcay, R. P., Curran, K., & Pető, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010099 · Cited by 3
Pető, T., Vujosevic, S., Sheth, V. S., Downey, A., Gibson, K., & Pollreisz, A. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01233-9 · Cited by 3
Fernández‐Vigo, J. I., Burgos‐Blasco, B., Calvo-González, C., Escobar, M. J., Shi, H., Jiménez-Santos, M., Valverde-Megías, A., Reche-Frutos, J., López-Guajardo, L., & Donate-López, J. (2021) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2021.02.005 · Cited by 3
Liang, X., Shen, B., Ou, Z., An, H., & Li, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.930508 · Cited by 3
“Moreover, combination therapy reduced the burden on patients due to an intensive injection regimen and the requirement for multiple hospital visits (25).”
An Automatic Identification of Diabetic Macular Edema Using Transfer Learning
Prasad, Y. N., Bindu, C. S., Kumar, E. S., & Reddy, P. D. K. (2021) · Lecture notes in networks and systems · doi:10.1007/978-981-16-1941-0_53 · Cited by 3
Ceguera digna y degeneración macular asociada a la edad. Un necesario enfoque multidisciplinar
Fernández-Vigo, J. Á., Fernández‐Vigo, J. I., Garijo, P. S., & Donate-López, J. (2018) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2018.05.008 · Cited by 3
One-year Real-world Outcomes and Durability With Faricimab in Patients With Diabetic Macular Edema
Singh, R. P., Tabano, D. C., Borkar, D. S., Ali, F. S., Ahmed, A. M., Myrick, A. C., Zwick, E. D., Downey, A., Barteselli, G., & Leng, T. (2025) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20250825-02 · Cited by 2
Zani, A., Bugatti, A., Maceroni, E., Duheric, M., Uggeri, M., Manocha, E., Bertelli, M., d’Angelo, M., Cimini, A., Caccuri, F., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108042 · Cited by 2
Adjunct Nondamaging Focal Laser Reduces Intravitreal Injection Burden in Diabetic Macular Edema
Azzouz, L., Durrani, A. F., Zhou, Y., & Paulus, Y. M. (2023) · Photonics · doi:10.3390/photonics10101165 · Cited by 2
“A reduction in the number of anti-VEGF injections offers tangible benefits as frequent intravitreal injections impart a considerable burden to patients [24,44], their families, and our healthcare system [45].”
Investigating Flow-Induced Corrosion of Magnesium in Ophthalmological Milieu
Ferroni, M., Gaetano, F. D., Gastaldi, D., Cereda, M. G., & Boschetti, F. (2024) · Materials · doi:10.3390/ma17174404 · Cited by 2
“Compliance with therapy is a major issue in the field of chronic and degenerative diseases, with 39.8% of patients worldwide abandoning their clinical regimen, resulting in underdosing due to fear and anxiety associated with injections for wet-AMD [44,45].”
InfluentialMinnella, A. M., Picardi, S. M., Maceroni, M., Albanesi, F., Siena, E. D., Placidi, G., Caputo, C. G., Vico, U. D., Rizzo, S., & Falsini, B. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01751-5 · Cited by 2
“of intermittent and repeated injections [13, 14].”
Menzler, J., Neubauer, A. S., & Ziemssen, F. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.02.24 · Cited by 2
Deep Learning in Retinal Diseases Diagnosis: A Review
Aykat, Ş., & Senan, S. (2022) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-6684-4671-3.ch001 · Cited by 3
Nozaki, M., Wong, I. Y., Kawasaki, R., Lee, J. E., Takamura, Y., Lee, J. E., Yoshida, S., Shin, J. P., Kida, T., Chang, W., et al. (2022) · Journal of Retina · doi:10.21561/jor.2022.7.2.65 · Cited by 2
Brolucizumab and faricimab as new treatment options for diabetic macular edema: perspective
Wong, H. L., Fung, N. S. K., & Kwok, A. K. (2022) · Hong Kong Journal of Ophthalmology · doi:10.12809/hkjo-v26n2-327 · Cited by 3
Bhavsar, M., Maksane, N., Shah, U., Madhavan, A., Dhar, P., & Thaker, M. (2021) · Indian Journal of Clinical and Experimental Ophthalmology · doi:10.18231/j.ijceo.2021.102 · Cited by 1
Alavanthar, T., & Madheswaran, M. (2024) · Traitement du signal · doi:10.18280/ts.410311 · Cited by 1
“DME affects around 26.7 million individuals, and it is anticipated that this figure will increase to almost 50 million by 2025 [5-8].”
InfluentialANTERIOR SUBTENON TRIAMCINOLONE INJECTION FOR REFRACTORY MACULAR EDEMA
Felfeli, T., Park, M., Gorfinkel, N., Shwarzman, R., Papanikolaou, J., Shah, P., Kiss, A., & Mandelcorn, E. D. (2024) · Retina · doi:10.1097/iae.0000000000004274 · Cited by 1
Metadata
- Authors
- Sivaprasad, S., & Oyetunde, S.
- Affiliations
- NIHR Moorfields Biomedical Research Centre (GB)
- Allergan (United Kingdom) (GB)
- Corresponding author
- Sivaprasad, Sobha
- ORCID
- Sivaprasad, Sobha
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 10
- Pages
- 939
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC4888735
- OpenAlex
- W2394715476
- Cited by
- 134
- References
- 35
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 15 · 2023: 13 · 2022: 10 · 2021: 14 · 2020: 16 · 2019: 6 · 2018: 10 · 2017: 9
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- diabetic macular edema, retinal vein occlusion, intravitreal injection, treatment burden, quality of life, treatment-related anxiety, absenteeism, appointment attendance, caregiver support, patient preferences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.